Reported by NDTV: “Abbot has a history of pricing this drug much higher in developed countries that it should. A number of public health advocates have asked that abbot lower the price or license it to other companies they refused So basically, we intervened in India because we knew that Indian companies will be able to make a more affordable version,” says Tahir M Amin, Director I-MAK.
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.